Meanwhile, GSK’s (NYSE:GSK) full-year revenue grew ~7% YoY to £31.3B as specialty medicines sales jumped 19% YoY and vaccine sales fell ~4% YoY. Meanwhile, its core earnings per share for Q4 ...

Explore how GSK's revenue and expenses shape its earnings. Looking ahead, revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the ...

GSK's 2024 Annual Report on Form 20-F is available online at GSK's website at: https://annualreport.gsk.com and also online at www.sec.gov. A hard copy version of the GSK 2024 Annual Report ...

The British pharmaceutical company’s depemokimab drug reduced asthma attacks in late-stage trials for patients with severe ...

Please consult the full Prescribing Information for additional ... those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q4 Results for ...

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow ...